Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Mouse (Murine) PLAUR Antikörper:
anti-Human PLAUR Antikörper:
anti-Rat (Rattus) PLAUR Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Mouse (Murine) Polyclonal PLAUR Primary Antibody für BR, CyTOF - ABIN5013025
Zhang, Cai, López-Guisa, Collins, Eddy: Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein. in Journal of the American Society of Nephrology : JASN 2004
Show all 7 Pubmed References
Human Polyclonal PLAUR Primary Antibody für WB - ABIN1944762
Roldan, Cubellis, Masucci, Behrendt, Lund, Danø, Appella, Blasi: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. in The EMBO journal 1990
Show all 5 Pubmed References
Human Polyclonal PLAUR Primary Antibody für IHC (p), WB - ABIN966859
Wang, Yang, Jamaluddin, Boyd: The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells. in The Journal of biological chemistry 2004
Show all 2 Pubmed References
Mouse (Murine) Polyclonal PLAUR Primary Antibody für FACS, WB - ABIN4900558
van Zoelen, Florquin, de Beer, Pater, Verstege, Meijers, van der Poll: Urokinase plasminogen activator receptor-deficient mice demonstrate reduced hyperoxia-induced lung injury. in The American journal of pathology 2009
Show all 2 Pubmed References
Rat (Rattus) Polyclonal PLAUR Primary Antibody für WB - ABIN223401
Viswanathan, Richardson, Togonu-Bickersteth, Dai, Liu, Vatsya, Sun, Yu, Munuswamy-Ramanujam, Baker, Lucas: Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B. in Journal of leukocyte biology 2009
Human Monoclonal PLAUR Primary Antibody für FACS - ABIN2472715
Gadd, Majdic, Kasinrerk, Stockinger, Maurer, Eher, Knapp: M5, a phosphoinositol-linked human myelomonocytic activation-associated antigen. in Clinical and experimental immunology 1990
Show all 3 Pubmed References
Human Monoclonal PLAUR Primary Antibody für IHC (fro), FACS - ABIN2472714
Sillaber, Baghestanian, Hofbauer, Virgolini, Bankl, Füreder, Agis, Willheim, Leimer, Scheiner, Binder, Kiener, Bevec, Fritsch, Majdic, Kress, Gadner, Lechner, Valent: Molecular and functional characterization of the urokinase receptor on human mast cells. in The Journal of biological chemistry 1997
Show all 3 Pubmed References
Human Monoclonal PLAUR Primary Antibody für FACS - ABIN2472717
Mondino, Blasi: uPA and uPAR in fibrinolysis, immunity and pathology. in Trends in immunology 2004
Show all 3 Pubmed References
The ratio of full-length versus cleaved uPAR as analysed by Western blotting and its regulation was assessed by addition of different protease inhibitors and transforming growth factor - beta1 (TGF-beta1 (zeige TGFB1 Antikörper)). The role of uPAR cleavage in cell proliferation and migration was analysed using real-time cell analysis and invasion was assessed using the myoma invasion model
Plg-RKT (zeige PLGRKT Antikörper) is required for plasminogen (zeige PLG Antikörper) binding and macrophage migration in vivo
The synergy of circulating factor suPAR and APOL1 (zeige APOL1 Antikörper) G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD.
Results identify soluble uPAR as a functional connection between the bone marrow and the kidney, and they implicate bone marrow immature myeloid cells as a key source of soluble uPAR that leads to glomerular dysfunction.
Plaur deficiency does not increase susceptibility to epileptogenesis after traumatic brain injury in an animal model.
Significance of the urokinase-type plasminogen activator (zeige PLAU Antikörper) and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Findings indicate a significant correlation of uPAR cleavage with breast cancer progression, but the precise biological consequence(s) of the cleavage or the cleavage products still remains to be elucidated.
interaction of full-length suPAR with alphavbeta3 integrin expressed on podocytes results in down-modulation of nephrin (zeige NPHS1 Antikörper) that may affect kidney functionality in different human pathologies characterized by increased concentration of suPAR.
In an in vivo murine angiogenesis model uPAR-deficient PTEN heterozygous animals increased the impaired angiogenic phenotype of uPAR knockout mice and were able to reverse the high invasive potential of PTEN heterozygotes.
uPAR contributes to macrophage driven atherosclerotic lesion formation.
Increased uPAR expression was detected in the derma of psoriatic lesions and in the stroma surrounding tumor cells in basal cell carcinomas.
study provides strong support in the role of L. reuteri in suppression of GC cell invasion by downregulation of pathways which is involved in extracellular matrix degradation such as uPA (zeige PRAP1 Antikörper) and uPAR
Plasma plasminogen activator urokinase receptor (P-suPAR) concentrations are elevated in acute alcohol pancreatitis (AAP (zeige APEH Antikörper)) and correlate with the severity of the disease, suggesting P-suPAR may serve as a prognostic marker for AAP (zeige APEH Antikörper) severity on admission.
We show that the tumor-suppressive actions of MEPs are mediated by PAI-1 (zeige SERPINE1 Antikörper), uPA (zeige PRAP1 Antikörper) and its receptor, uPAR, and are sustained even in the presence of the CAFs (zeige TBX1 Antikörper), which themselves enhance DCIS tumorigenesis via IL-6 (zeige IL6 Antikörper) signaling.
We report on the impact of bispecific targeting on the toxicity risks associated with targeting of EGFR (zeige EGFR Antikörper) and uPAR . Our results show that eBAT is safe and potentially effective at biologically active doses despite EGFR (zeige EGFR Antikörper) targeting, supporting further translation for patients with sarcomas and other EGFR (zeige EGFR Antikörper)-expressing malignancies.
Improved positron emission tomography imaging of glioblastoma cancer using novel (68)Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR).
uPA (zeige PRAP1 Antikörper)/uPAR and SERPINE1 (zeige SERPINE1 Antikörper) have roles in in head and neck cancer tumor resistance, metastasis, prognosis and therapy [review]
Sera and tissues from malignant mesothelioma (MM) patients showed significantly high plasminogen activator urokinase receptor (uPAR) levels, suggesting the pathogenic role of uPAR in the tumor biology of MM.
Levels of circulating cleaved soluble forms plasminogen activator urokinase receptor (DIIDIII-suPAR) in acute myeloid leukemia (zeige BCL11A Antikörper) (AML (zeige RUNX1 Antikörper)) patients are higher as compared to controls and significantly decrease after the conditioning.
Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication
Data show that urokinase-type plasminogen activator (uPA (zeige PLAU Antikörper)) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA (zeige PLAU Antikörper) receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1 (zeige SERPINE1 Antikörper)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA (zeige PLAU Antikörper)/uPAR binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
Data indicate that superoxide dismutase (SOD) inhibited high glucose (HG)-induced expression of uPAR and VEGF in bovine retinal microvascular endothelial cell (REC).
These data indicated that E. coli LPS (zeige IRF6 Antikörper) led to an increase in u-PA (zeige PLAU Antikörper) activity and RNA expression of u-PA (zeige PLAU Antikörper) and u-PAR in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
the interaction between uPAR and Man-6-P/IGF2R (zeige IGF2R Antikörper) is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/IGF2R (zeige IGF2R Antikörper) by different mechanisms.
This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.
urokinase plasminogen activator surface receptor
, plasminogen activator, urokinase receptor
, urokinase plasminogen activator receptor
, urokinase-type plasminogen activator receptor
, monocyte activation antigen Mo3
, u-plasminogen activator receptor form 2
, urokinase-type plasminogen activator (uPA) receptor
, plasminogen activator urokinase receptor 3
, urinary plasminogen activator receptor 2
, urinary plasminogen activator receptor 3